bioAffinity Technologies, Inc. announced on September 19, 2025, that it would effect a 1-for-30 reverse split of its common stock, effective at the open of trading on the Nasdaq Capital Market on the same day. The company's common stock will trade on a post-split basis under the symbol BIAF.
The reverse stock split was approved by the company’s stockholders at the annual meeting held on July 25, 2025. This action is primarily intended to bring the company into compliance with Nasdaq’s minimum bid price requirement, which is crucial for maintaining its listing.
As a result of the reverse stock split, every 30 shares of issued and outstanding common stock will be exchanged for one share, resulting in approximately 1,338,029 shares of common stock issued and outstanding immediately after the split. Proportionate adjustments will be made to the exercise prices and number of shares underlying outstanding stock options and warrants.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.